Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gautier Marcq

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
European Urology Focus|June 21, 2024
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract CancerSinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, et al.
BJU International|March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancerMarkus von Deimling, Laura S Mertens, Marc Furrer, et al.
BJU International|March 20, 2026
Refining BCG-failure classifications in non-muscle-invasive bladder cancerAleksander Ślusarczyk, Pietro Scilipoti, Roberto Contieri, et al.
European Urology Open Science|March 4, 2025
Renal Mass Biopsy Prior to Surgical Excision: Practice, Diagnostic Performance, and Impact on Management in the UroCCR Registry (Ancillary Study No. 118)Pauline Proye, Bastien Gondran-Tellier, Floriane Michel, et al.
BJU International|July 4, 2024
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleedingLuca Antonelli, Pedro David Wendel-Garcia, Manja Deforth, et al.
European Urology Oncology|December 19, 2025
Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC CohortElisabeth Grobet-Jeandin, Elliott Diamant, Pierre-Etienne Gabriel, et al.
Minerva Urology and Nephrology|September 20, 2023
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapyRadosław Piszczek, Wojciech Krajewski, Jose D Subiela, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Surgical Oncology|March 21, 2026
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder CancerAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
European Urology Focus|June 21, 2024
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract CancerSinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, et al.
BJU International|March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancerMarkus von Deimling, Laura S Mertens, Marc Furrer, et al.
BJU International|March 20, 2026
Refining BCG-failure classifications in non-muscle-invasive bladder cancerAleksander Ślusarczyk, Pietro Scilipoti, Roberto Contieri, et al.
European Urology Open Science|March 4, 2025
Renal Mass Biopsy Prior to Surgical Excision: Practice, Diagnostic Performance, and Impact on Management in the UroCCR Registry (Ancillary Study No. 118)Pauline Proye, Bastien Gondran-Tellier, Floriane Michel, et al.
BJU International|July 4, 2024
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleedingLuca Antonelli, Pedro David Wendel-Garcia, Manja Deforth, et al.
European Urology Oncology|December 19, 2025
Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC CohortElisabeth Grobet-Jeandin, Elliott Diamant, Pierre-Etienne Gabriel, et al.
Minerva Urology and Nephrology|September 20, 2023
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapyRadosław Piszczek, Wojciech Krajewski, Jose D Subiela, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Surgical Oncology|March 21, 2026
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder CancerAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Pageof 10